Biology and treatment of follicular lymphoma

Expert Review of Hematology

Volumn 2, Issue 5, 2009, Pages 533-547

  Piccaluga, Pier Paolo ^a   Sapienza, Maria Rosaria ^a   Agostinelli, Claudio ^a   Sagramoso, Carlo ^a   Mannu, Claudia ^a   Sabattini, Elena ^a   Zinzani, Pier Luigi ^a   Pileri, Stefano A ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

BCL2; FISH; Follicular lymphoma; Gene expression profiling; Immunohistochemistry; Minimal residual disease; Monoclonal antibodies; Targeted therapy; WHO classification

Indexed keywords

CD19 ANTIGEN; CD20 ANTIGEN; CD79A ANTIGEN; CHLORAMBUCIL; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPRATUZUMAB; GALIXIMAB; IBRITUMOMAB TIUXETAN; MITOXANTRONE; MONOCLONAL ANTIBODY; OFATUMUMAB; PREDNISONE; PROTEIN BCL 2; PROTEIN BCL 6; RITUXIMAB; TENIPOSIDE; VELTUZUMAB; VINCRISTINE; VINCRISTINE SULFATE;

CHROMOSOME TRANSLOCATION 14; CHROMOSOME TRANSLOCATION 18; FOLLICULAR LYMPHOMA; GERMINAL CENTER; HUMAN; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, FOLLICULAR; NITROGEN MUSTARD COMPOUNDS;

EID: 77953474841     PISSN: 17474086     EISSN: None     Source Type: Journal    
DOI: 10.1586/ehm.09.49     Document Type: Review

References (135)

1. Harris N, Swerdlow S, Jaffe E et al. Follicular lymphoma. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Swerdlow S, Campo E, Harris N et al. (Eds). IARC Press, Lyon, France 220-226 (2008).
2. Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann. Oncol. 9(7), 717-720 (1998).
3. A clinical evaluation of the international lymphoma study group classification of non-Hodgkin lymphoma. The non-Hodgkin lymphoma classification project. Blood 89, 3909-3918 (1997).
4. Morton LM, Wang SS, Cozen W et al. Etiologic heterogeneity among non-Hodgkin lymphoma subtypes. Blood 112(13), 5150-5160 (2008).
5. Fritschi L, Benke G, Hughes AM et al. Occupational exposure to pesticides and risk of non-Hodgkin's lymphoma. Am. J. Epidemiol. 162(9), 849-857 (2005).
6. Orsi L, Delabre L, Monnereau A et al. Occupational exposure to pesticides and lymphoid neoplasms among men: results of a French case-control study. Occup. Environ. Med. 66(5), 291-298 (2009).
7. McDuffie HH, Pahwa P, McLaughlin JR et al. Non-Hodgkin's lymphoma and specific pesticide exposures in men: cross-Canada study of pesticides and health. Cancer Epidemiol. Biomarkers Prev. 10(11), 1155-1163 (2001).
8. Czuczman MS. Controversies in follicular lymphoma: "who, what, when, where, and why?" (not necessarily in that order!). Hematology Am. Soc. Hematol. Educ. Program 2006, 303-310 (2006).
9. Piccaluga PP, Califano A, Klein U et al. Gene expression analysis provides a potential rationale for revising the histological grading of follicular lymphomas. Haematologica 93(7), 1033-1038 (2008).
10. Lennert K, Mohri N. Histopathology and diagnosis of non Hodgkin's lymphomas. In: Malignant Lymphoma Other Than Hodgkin Disease. Lennert K, Mohri N, Stein H, Kaiserling E, Müller-Hermelinck HK (Eds). Springer-Verlag, Heidelberg, Germany 111-470 (1978).
11. Robetorye RS, Bohling SD, Medeiros LJ, Elenitoba-Johnson KS. Follicular lymphoma with monocytoid B-cell proliferation: molecular assessment of the clonal relationship between the follicular and monocytoid B-cell components. Lab. Invest. 80(10), 1593-1599 (2000).
12. Guo Y, Karube K, Kawano R et al. Bcl2-negative follicular lymphomas frequently have Bcl6 translocation and/or Bcl6 or p53 expression. Pathol. Int. 57(3), 148-152 (2007).
13. Alvaro T, Lejeune M, Salvado MT et al. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J. Clin. Oncol. 24(34), 5350-5357 (2006).
14. Carreras J, Lopez-Guillermo A, Fox BC et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 108(9), 2957-2964 (2006).
15. de Jong D, Koster A, Hagenbeek A et al. Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols. Haematologica 94(1), 70-77 (2009).
16. Karube K, Guo Y, Suzumiya J et al. CD10-MUM1+ follicular lymphoma lacks BCL2 gene translocation and shows characteristic biologic and clinical features. Blood 109(7), 3076-3079 (2007).
17. Naresh KN. MUM1 expression dichotomises follicular lymphoma into predominantly, MUM1-negative low-grade and MUM1-positive high-grade subtypes. Haematologica 92(2), 267-268 (2007).
18. Finn LS, Viswanatha DS, Belasco JB et al. Primary follicular lymphoma of the testis in childhood. Cancer 85(7), 1626-1635 (1999).
19. Lorsbach RB, Shay-Seymore D, Moore J et al. Clinicopathologic analysis of follicular lymphoma occurring in children. Blood 99(6), 1959-1964 (2002).
20. Swerdlow SH. Pediatric follicular lymphomas, marginal zone lymphomas, and marginal zone hyperplasia. Am. J. Clin. Pathol. 122(Suppl.), S98-S109 (2004).
21. Misdraji J, Fernandez del Castillo C, Ferry JA. Follicle center lymphoma of the ampulla of Vater presenting with jaundice: report of a case. Am. J. Surg. Pathol. 21(4), 484-488 (1997).
22. Sato Y, Ichimura K, Tanaka T et al. Duodenal follicular lymphomas share common characteristics with mucosaassociated lymphoid tissue lymphomas. J. Clin. Pathol. 61(3), 377-381 (2008).
23. Shia J, Teruya-Feldstein J, Pan D et al. Primary follicular lymphoma of the gastrointestinal tract: a clinical and pathologic study of 26 cases. Am. J. Surg. Pathol. 26(2), 216-224 (2002).
24. Yoshino T, Miyake K, Ichimura K et al. Increased incidence of follicular lymphoma in the duodenum. Am. J. Surg. Pathol. 24(5), 688-693 (2000).
25. Hoefnagel JJ, Vermeer MH, Jansen PM, Fleuren GJ, Meijer CJ, Willemze R. Bcl-2, Bcl-6 and CD10 expression in cutaneous B-cell lymphoma: further support for a follicle centre cell origin and differential diagnostic significance. Br. J. Dermatol. 149(6), 1183-1191 (2003).
26. Senff NJ, Hoefnagel JJ, Jansen PM et al. Reclassification of 300 primary cutaneous B-Cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers. J. Clin. Oncol. 25(12), 1581-1587 (2007).
27. Mirza I, Macpherson N, Paproski S et al. Primary cutaneous follicular lymphoma: an assessment of clinical, histopathologic, immunophenotypic, and molecular features. J. Clin. Oncol. 20(3), 647-655 (2002).
28. Kodama K, Massone C, Chott A, Metze D, Kerl H, Cerroni L. Primary cutaneous large B-cell lymphomas: clinicopathologic features, classification, and prognostic factors in a large series of patients. Blood 106(7), 2491-2497 (2005).
29. Cerroni L, Rieger E, Hodl S, Kerl H. Clinicopathologic and immunologic features associated with transformation of mycosis fungoides to large-cell lymphoma. Am. J. Surg. Pathol. 16(6), 543-552 (1992).
30. Cerroni L, Volkenandt M, Rieger E, Soyer HP, Kerl H. bcl-2 protein expression and correlation with the interchromosomal 14;18 translocation in cutaneous lymphomas and pseudolymphomas. J. Invest. Dermatol. 102(2), 231-235 (1994).
31. Child FJ, Russell-Jones R, Woolford AJ et al. Absence of the t(14;18) chromosomal translocation in primary cutaneous B-cell lymphoma. Br. J. Dermatol. 144(4), 735-744 (2001).
32. Burg G, Kempf W, Cozzio A et al. WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects. J. Cutan. Pathol. 32(10), 647-674 (2005).
33. Tsujimoto Y, Gorham J, Cossman J, Jaffe E, Croce CM. The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science 229(4720), 1390-1393 (1985).
34. McDonnell TJ, Deane N, Platt FM et al. bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 57(1), 79-88 (1989).
35. Schuler F, Dolken L, Hirt C et al. Prevalence and frequency of circulating t(14;18)-MBR translocation carrying cells in healthy individuals. Int. J. Cancer 124(4), 958-963 (2009).
36. Zignego AL, Giannelli F, Marrocchi ME et al. t(14;18) translocation in chronic hepatitis C virus infection. Hepatology (Baltimore) 31(2), 474-479 (2000).
37. Ladetto M, Mantoan B, De Marco F et al. Cells carrying nonlymphoma-associated bcl-2/IgH rearrangements (NLABR) are phenotypically related to follicular lymphoma and can establish as long-term persisting clonal populations. Exp. Hematol. 34(12), 1680-1686 (2006).
38. Roulland S, Navarro JM, Grenot P et al. Follicular lymphoma-like B cells in healthy individuals: a novel intermediate step in early lymphomagenesis. J. Exp. Med. 203(11), 2425-2431 (2006).
39. Zelenetz AD, Chen TT, Levy R. Clonal expansion in follicular lymphoma occurs subsequent to antigenic selection. J. Exp. Med. 176(4), 1137-1148 (1992).
40. Klein U, Dalla-Favera R. Germinal centres: role in B-cell physiology and malignancy. Nat. Rev. Immunol. 8(1), 22-33 (2008)
41. Klein U, Tu Y, Stolovitzky GA et al. Transcriptional analysis of the B cell germinal center reaction. Proc. Natl Acad. Sci. USA 100(5), 2639-2644 (2003).
42. Ott G, Rosenwald A. Molecular pathogenesis of follicular lymphoma. Haematologica 93(12), 1773-1776 (2008).
43. Tsujimoto Y, Cossman J, Jaffe E, Croce CM. Involvement of the bcl-2 gene in human follicular lymphoma. Science 228(4706), 1440-1443 (1985).
44. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348(6299), 334-336 (1990).
45. Yang E, Korsmeyer SJ. Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood 88(2), 386-401 (1996).
46. Braziel RM, Shipp MA, Feldman AL et al. Molecular diagnostics. Hematology Am. Soc. Hematol. Educ. Program 2003, 279-293 (2003).
47. Bende RJ, Smit LA, van Noesel CJ. Molecular pathways in follicular lymphoma. Leukemia 21(1), 18-29 (2007).
48. Carlotti E, Wrench D, Matthews J et al. Transformation of follicular lymphoma to diffuse large B-cell lymphoma may occur by divergent evolution from a common progenitor cell or by direct evolution from the follicula lymphoma clone. Blood 113(15), 3553-3557 (2009).
49. Bohen SP, Troyanskaya OG, Alter O et al. Variation in gene expression patterns in follicular lymphoma and the response to rituximab. Proc. Natl Acad. Sci. USA 100(4), 1926-1930 (2003).
50. Dave SS, Wright G, Tan B et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N. Engl. J. Med. 351(21), 2159-2169 (2004).
51. Farinha P, Masoudi H, Skinnider BF et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 106(6), 2169-2174 (2005).
52. Glas AM, Knoops L, Delahaye L et al. Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J. Clin. Oncol. 25(4), 390-398 (2007).
53. Lossos IS, Alizadeh AA, Diehn M et al. Transformation of follicular lymphoma to diffuse large-cell lymphoma: alternative patterns with increased or decreased expression of c-myc and its regulated genes. Proc. Natl Acad. Sci. USA 99(13), 8886-8891 (2002).
54. Cleary ML, Sklar J. Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc. Natl Acad. Sci. USA 82(21), 7439-7443 (1985).
55. Bakhshi A, Wright JJ, Graninger W et al. Mechanism of the t(14;18) chromosomal translocation: structural analysis of both derivative 14 and 18 reciprocal partners. Proc. Natl Acad. Sci. USA 84(8), 2396-2400 (1987).
56. Albinger-Hegyi A, Hochreutener B, Abdou MT et al. High frequency of t(14;18)-translocation breakpoints outside of major breakpoint and minor cluster regions in follicular lymphomas: improved polymerase chain reaction protocols for their detection. Am. J. Pathol. 160(3), 823-832 (2002).
57. Winter JN, Gascoyne RD, Van Besien K. Low-grade lymphoma. Hematology Am. Soc. Hematol. Educ. Program 2004, 203-220 (2004).
58. Aster JC, Longtine JA. Detection of BCL2 rearrangements in follicular lymphoma. Am. J. Pathol. 160(3), 759-763 (2002).
59. Schuler F, Dolken S, Hirt C, Dolken G. Multiplex quantitative real-time PCR for the detection of t(14;18) translocations with breakpoints within 5 different regions of the BCL-2 gene: MBR, 3́MBR, mcr, 5́mcr, icr. ASH Annual Meeting Abstracts 106, 2826 (2005).
60. Korsmeyer SJ. Chromosomal translocations in lymphoid malignancies reveal novel proto-oncogenes. Annu. Rev. Immunol. 10, 785-807 (1992).
61. Pezzella F, Ralfkiaer E, Gatter KC, Mason DY. The 14;18 translocation in European cases of follicular lymphoma: comparison of Southern blotting and the polymerase chain reaction. Br. J. Haematol. 76(1), 58-64 (1990).
62. Espinet B, Bellosillo B, Melero C et al. FISH is better than BIOMED-2 PCR to detect IgH/BCL2 translocation in follicular lymphoma at diagnosis using paraffin-embedded tissue sections. Leuk. Res. 32(5), 737-742 (2008).
63. van Dongen JJ, Langerak AW, Bruggemann M et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17(12), 2257-2317 (2003).
64. Godon A, Moreau A, Talmant P et al. Is t(14;18)(q32;q21) a constant finding in follicular lymphoma? An interphase FISH study on 63 patients. Leukemia 17(1), 255-259 (2003).
65. Gu K, Hawley RC, Cankovic M, Whitely L, Sanchez J, Adeyinka A. Comparison of FISH and PCR for detection of t(14;18) in folicular lymphomas. Mod. Pathol. 19(S1), 229a (2006).
66. Barrans SL, Evans PA, O'Connor SJ, Owen RG, Morgan GJ, Jack AS. The detection of t(14;18) in archival lymph nodes: development of a fluorescence in situ hybridization (FISH)-based method and evaluation by comparison with polymerase chain reaction. J. Mol. Diagn. 5(3), 168-175 (2003).
67. Cook JR. Paraffin section interphase fluorescence in situ hybridization in the diagnosis and classification of non-Hodgkin lymphomas. Diagn. Mol. Pathol. 13(4), 197-206 (2004).
68. Jiang F, Lin F, Price R et al. Rapid detection of IgH/BCL2 rearrangement in follicular lymphoma by interphase fluorescence in situ hybridization with bacterial artificial chromosome probes. J. Mol. Diagn. 4(3), 144-149 (2002).
69. Lee MS, Chang KS, Cabanillas F, Freireich EJ, Trujillo JM, Stass SA. Detection of minimal residual cels carrying the t(14;18) by DNA sequence amplification. Science 237, 175-178 (1987).
70. Finke J, Slanina J, Lange W, Dolken G. Persistence of circulating t(14;18)-positive cells in long-term remission after radiation therapy for localized-stage follicular lymphoma. J. Clin. Oncol. 11, 1668-1673 (1993).
71. Gribben JG, Freedman A, Woo SD et al. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood 78, 3275-3280 (1991).
72. Gribben JG, Freedman AS, Neuberg D, Roy DC, Blake KW, Woo SD et al. Immunologic purging of marrow assesed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N. Engl. J. Med. 325, 1525-1533 (1991).
73. Rambaldi A, Lazzari M, Manzoni Cea. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with folicular lymphoma. Blood 99, 856-862 (2002).
74. Dolken L, Schuler F, Dolken G. Quantitative detection of t(14;18)-positive cells by real-time quantitative PCR using fluorogenic probes. Biotechniques 25, 1058-1064 (1998).
75. Luthra, McBride JA, Cabanillas F, A. S. Novel 5́ exonuclease-based real-time PCR assay for the detection of t(14;18)(q32;q21) in patients with folicular lymphoma. Am. J. Clin. Pathol. 153, 63-68 (1998).
76. Morschhauser F, Radford J, Van Hoof A et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J. Clin. Oncol. 26(32), 5156-5164 (2008).
77. Lepage E, Sebban C, Gisselbrecht C. Treatment of low-grade non-Hodgkin's lymphomas: assessment of doxorubicin in a controlled trial. Hematol. Oncol. 8, 31-39 (1990).
78. Gallagher CJ, Gregory WM, Jones AE et al. Follicular lymphoma: prognostic factors for response and survival. J. Clin. Oncol. 4, 1470-1480 (1986).
79. Buckstein R, Pennell N, Berinstein N. What is remission in follicular lymphoma and what is its relevance? Best Pract. Res. Clin. Haematol. 18, 27-56 (2005).
80. Ladetto M, Corradini P, Vallet S et al. High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Blood 100(5), 1559-1565 (2002).
81. Lopez-Guillermo A, Cabanillas F, McLaughlin P et al. The clinical significance of molecular response in indolent follicular lymphoma. Blood 91, 2955-2960 (1998).
82. Haas R, Moos M, Karcher A et al. Sequential high-dose therapy with peripheral-blood progenitor-cell support in low-grade non-Hodgkin's lymphoma. J. Clin. Oncol. 12, 1685-1692 (1994).
83. Ha CS, Tucker SL, Blanco AI et al. Hematologic recovery after central lymphatic irradiation for patients with stage I-III follicular lymphoma. Cancer 92, 1074-1079 (2001).
84. Price CG, Meerabux J, Murtagh S et al. The significance of circulating cells carrying t(14;18) in long remission from follicular lymphoma. J. Clin. Oncol. 9, 1527-1532 (1991).
85. Lambrechts AC, Hupkes PE, Dorssers LC, van't Veer MB. Clinical significance of t(14;18)-positive cells in the circulation of patients with stage III or IV folicular non-Hodgkin's lymphoma during first remission. J. Clin. Oncol. 12, 1541-1546 (1994).
86. McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16(8), 2825-2833 (1998).
87. Colombat P, Brousse N, Morschhauser F. Single treatment with rituximab monotherapy for low-tumor burden follicular lymphoma (FL): survival analyses with extended follow-up of 7 years. Blood 108, 147a (2006) (Abstract 486).
88. Ghielmini M, Schmitz SF, Cogliatti SB et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule. Blood 103(12), 4416-4423 (2004).
89. Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma-a randomized Phase II trial of the Minnie Pearl Cancer Research Network. J. Clin. Oncol. 23(6), 1088-1095 (2005).
90. Hiraga J, Tomita A, Sugimoto T et al. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood 113(20), 4885-4893 (2009).
91. Buske C, Hoster E, Dreyling M, Hasford J, Unterhalt M, Hiddemann W. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate-or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 108(5), 1504-1508 (2006).
92. Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother. Radiopharm. 12(3), 177-186 (1997).
93. Hiddemann W, Kneba M, Dreyling M et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106(12), 3725-3732 (2005). (Pubitemid 41742196)
94. Marcus R, Imrie K, Belch A et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105(4), 1417-1423 (2005).
95. Herold M, Haas A, Srock S et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J. Clin. Oncol. 25(15), 1986-1992 (2007).
96. Salles G, Mounier N, de Guibert S et al. Rituximab combined with chemotherapy and interferon in folicular lymphoma patients: final analysis of the GELA GOELAMS FL2000 study with a 5-year follow-up. Blood 110, 243a (2007) (Abstract 792).
97. Friedberg JW, Cohen P, Chen L et al. Bendamustine in patients with rituximabrefractory indolent and transformed non-Hodgkin's lymphoma: results from a Phase II multicenter, single-agent study. J. Clin. Oncol. 26(2), 204-210 (2008).
98. Kahl B, Bardett N, Leonard J. Bendamustine is safe and effective in patients with rituximab-refractory, indolent B-cell non-Hodgkins lymphoma. Blood 110, 406a (2007) (Abstract 1351).
99. Kath R, Blumenstengel K, Fricke HJ, Peters HD, Höffken K. Bendamustine, vincristine, prednisolone (BOP) in therapy of advanced low-grade non Hodgkin lymphoma. Dtsch Med. Wochenschr. 126(8), 198-202 (2001)
100. Ruffert K. Therapy of low grade nonhodkin's lymphoma (NHL) with bendamustine and oral etoposide. Ann. Oncol. 10(Suppl. 3), 125 (1999) (Abstract 452).
101. Herold M, Schulze A, Niederwieser D et al. Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised Phase III trial (OSHO# 19). J. Cancer Res. Clin. Oncol. 132(2), 105-112 (2006).
102. Rummel M, Atta J, Welslau M. Bendamustine and rituximab (BR) are effective in the treatment of the relapsed or refractory indolent and mantle cell lymphoma: long-term follow-up of a Phase II study. J. Clin. Oncol. 25(18 Suppl.), S449 (2007) (Abstract 8043).
103. Rummel M, Von Grunhagen V, Niederle N. Bendamustine plus rituximab versus CHOP plus rituximab in the first-line treatment of patients with indolent and mantle cell lymphomas first interim results of a randomized Phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood 110, 120a (2007) (Abstract 385).
104. Teeling JL, French RR, Cragg MS et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104(6), 1793-1800 (2004).
105. Hagenbeek A, Plesner T, Johnson P et al. HuMax-CD20, a novel fully human anti-CD20 monoclonal antibody: results of a Phase I/II trial in relapsed or refractory follicular non-Hodgkins' Lymphoma. (ASH Annual Meeting Abstracts) Blood 106, 4760 (2005).
106. Stein R, Qu Z, Chen S et al. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin. Cancer Res. 10(8), 2868-2878 (2004).
107. Morschhauser F, Leonard J, Fayad LE et al. Low doses of humanized anti-CD20 antibody, IMMU-106 (hA20), in refractory or recurrent NHL: Phase I/II results. (ASCO Annual Meeting Proceedings Part I). J. Clin. Oncol. 25(18S), 8032 (2007).
108. Umana P, Moessner E, Bruenker P et al. Novel 3rd generation humanized type II CD20 antibody with glycoengineered Fcand modified elbow hinge for enhanced ADCC and superior apoptosis induction. (ASH Annual Meeting Abstracts) Blood 108, 229 (2006).
109. Weiner G, Bowles J, Link BK et al. Anti-CD20 monoclonal antibody (mAb) with enanched affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab (R). (ASH Annual Meeting Abstracts) Blood 106, 348 (2005).
110. Leonard JP, Coleman M, Ketas JC et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J. Clin. Oncol. 21(16), 3051-3059 (2003).
111. Leonard JP, Coleman M, Ketas J et al. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J. Clin. Oncol. 23(22), 5044-5051 (2005).
112. Advani R, Forero-Torres A, Furman RR et al. SGN-40 (anti-HuCO40 mAb) monotherapy induces durable objective responses in patiens with relapsed aggressive non-Hodgkin's lymphoma: evidence of antitumor activity tram a Phase I study. (ASH Annual Meeting Abstracts) Blood 108, 695 (2006).
113. Czuczman MS, Thall A, Witzig TE et al. Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J. Clin. Oncol. 23(19), 4390-4398 (2005).
114. Friedberg JW, Leonard JP, Younes A. Updated results from a Phase II study of galiximab (anti-CD80) in combination with rituximab for relapsed or refractory, follicular NHL. (ASH Annual Meeting Abstracts) Blood 106, 2435 (2005).
115. Witzig TE, Flinn IW, Gordon LI et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J. Clin. Oncol. 20(15), 3262-3269 (2002).
116. Gordon LI, Witzig TE, Molina A, Czuczman M, Emmanouilides C, Joyce R. Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin. Lymphoma 5, 98-101 (2004).
117. Schilder RJ, Ansell S, Pierslor P, Gordon L, Emmanouilides C, Czuczman Mea. Subsequent therapy for non-Hodgkin's lymphoma is feasible after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan (Zevalin). (EHA Meeting Abstracts) Hematol. J. 5, S7 (2004) (Abstract 019).
118. Witzig TE, Gordon LI, Cabanillas F et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 20(10), 2453-2463 (2002).
119. Witzig TE, Molina A, Gordon LI et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer 109(9), 1804-1810 (2007). (Pubitemid 46668544)
120. Wiseman GA, Witzig TE. Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Cancer Biother. Radiopharm. 20(2), 185-188 (2005).
121. Cheung MC, Haynes AE, Stevens A, Meyer RM, Imrie K. Yttrium 90 ibritumomab tiuxetan in lymphoma. Leuk. Lymphoma 47(6), 967-977 (2006).
122. Ogura M, Moroshima Y, Watanbe T. 90Y ibritumomab tiuxen (Y2B8, Zevalin) radioimmunoteraphy (RIT) is highly effective for relapsed or refractory indolent B-cell non-Hodgkin (B-NHL) pretreated with rituximab-containing chemotherapy (R-chemo): Japanese Multicenter Phase II Study. (ASH Annual Meeting Abstracts) Blood 108 (2006) (Abstract 783a).
123. Press OW, Unger JM, Braziel RM et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J. Clin. Oncol. 24(25), 4143-4149 (2006).
124. Zinzani PL, Tani M, Pulsoni A et al. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a Phase II non-randomised trial (FLUMIZ). Lancet Oncol. 9(4), 352-358 (2008).
125. Hochster H, Weller E, Gascoyne RD et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized Phase III ECOG1496 Study. J. Clin. Oncol. 27(10), 1607-1614 (2009).
126. Hainsworth JD, Litchy S, Burris HA 3rd et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J. Clin. Oncol. 20(20), 4261-4267 (2002).
127. van Oers MH, Klasa R, Marcus RE et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized Phase 3 intergroup trial. Blood 108(10), 3295-3301 (2006).
128. Forstpointner R, Unterhalt M, Dreyling M et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 108(13), 4003-4008 (2006).
129. Vidal L, Gafter-Gvili A, Leibovici L et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. J. Natl Cancer Inst. 101(4), 248-255 (2009).
130. Bendandi M, Gocke CD, Kobrin CB et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat. Med. 5(10), 1171-1177 (1999).
131. Inoges S, Rodriguez-Calvillo M, Zabalegui N et al. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J. Natl Cancer Inst. 98(18), 1292-1301 (2006).
132. Ai WZ, Tibshirani R, Taidi B, Czerwinski D, Levy R. Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma. Blood 113(23), 5743-5746 (2009).
133. Freedman A, Neelapu SS, Nichols C et al. Placebo-controlled Phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. J. Clin. Oncol. 27(18), 3036-3043 (2009).
134. Barr PM, Lazarus HM. Follicular non-Hodgkin lymphoma: long-term results of stem-cell transplantation. Curr. Opin. Oncol. 20(5), 502-508 (2008).
135. Ladetto M, Vallet S, Benedetti F et al. Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: updated results of the multicenter consecutive GITMO trial. Leukemia 20(10), 1840-1847 (2006).